QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

AbbVie Stock Price, News & Analysis (NYSE:ABBV)

$144.14
+0.73 (+0.51%)
(As of 12/4/2023 ET)
Compare
Today's Range
$143.27
$145.49
50-Day Range
$137.61
$153.91
52-Week Range
$130.96
$168.11
Volume
4.85 million shs
Average Volume
5.50 million shs
Market Capitalization
$254.48 billion
P/E Ratio
39.49
Dividend Yield
4.11%
Price Target
$167.94

AbbVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
16.5% Upside
$167.94 Price Target
Short Interest
Healthy
0.63% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.41mentions of AbbVie in the last 14 days
Based on 38 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-0.71%
From $11.24 to $11.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.00 out of 5 stars

Medical Sector

26th out of 952 stocks

Pharmaceutical Preparations Industry

8th out of 434 stocks


ABBV stock logo

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

ABBV Stock News Headlines

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts (ABBV)
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
These biotechs targeting multiple neurodegenerative diseases (ABBV)
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
These are the top sectors for blue chip growth in 2024 (ABBV)
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.
J&J, Gilead, BMS: A look at undervalued dividend payers (ABBV)
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Guidance leads the market for these stocks; 1 raises, 1 lowers
Guidance is a driving force for equity markets and can lead stock prices higher or lower, catalyze significant moves, and alter analysts' outlook
Here’s Why AbbVie (ABBV) Rose in Q3
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Raymond James Raises AbbVie (NYSE:ABBV) Price Target to $181.00
AbbVie: $10 Billion Cancer Deal To Boost Growth
Why Abbvie Stock Popped Today
AbbVie: Get Ready For More Painful Downside
Buy The Dip In AbbVie? Nope, Not This Time
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 11/15 Dividend
10/12/2023
Last Earnings
10/27/2023
Dividend Payable
11/15/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/08/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$167.94
High Stock Price Target
$196.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+16.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

Net Income
$11.84 billion
Pretax Margin
14.51%

Debt

Sales & Book Value

Annual Sales
$58.05 billion
Cash Flow
$18.79 per share
Book Value
$9.78 per share

Miscellaneous

Outstanding Shares
1,765,540,000
Free Float
1,760,947,000
Market Cap
$254.40 billion
Optionable
Optionable
Beta
0.48

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report














ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price target for 2024?

16 brokerages have issued 1-year price targets for AbbVie's shares. Their ABBV share price targets range from $150.00 to $196.00. On average, they expect the company's stock price to reach $167.94 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2023?

AbbVie's stock was trading at $161.61 at the beginning of 2023. Since then, ABBV shares have decreased by 10.8% and is now trading at $144.14.
View the best growth stocks for 2023 here
.

Are investors shorting AbbVie?

AbbVie saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 11,150,000 shares, a decrease of 15.7% from the October 31st total of 13,230,000 shares. Based on an average daily trading volume, of 4,700,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.6% of the shares of the stock are sold short.
View AbbVie's Short Interest
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our ABBV earnings forecast
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its earnings results on Friday, October, 27th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.09. The firm earned $13.93 billion during the quarter, compared to the consensus estimate of $13.72 billion. AbbVie had a trailing twelve-month return on equity of 152.70% and a net margin of 11.81%. AbbVie's quarterly revenue was down 6.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.66 EPS.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 27th. Shareholders of record on Tuesday, January 16th will be paid a dividend of $1.55 per share on Thursday, February 15th. This represents a $6.20 annualized dividend and a dividend yield of 4.30%. The ex-dividend date of this dividend is Friday, January 12th. This is a positive change from the stock's previous quarterly dividend of $1.48.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 4.13%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 162.19%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.05% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY24 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $10.70-11.00 for the period, compared to the consensus EPS estimate of $11.11.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (1.82%), Charles Schwab Investment Management Inc. (1.29%), Northern Trust Corp (1.24%), Bank of New York Mellon Corp (1.15%), Ameriprise Financial Inc. (0.80%) and Legal & General Group Plc (0.69%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
This page (NYSE:ABBV) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -